Astal Lab

{
  "main_header": {
    "sid": 157295,
    "name": "Astal Lab",
    "stock_name": "Astal Lab",
    "full_name": "Astal Laboratories Ltd",
    "name_url": "stocks-analysis/astal-lab",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "79.50",
    "chg": 2.01,
    "chgp": "2.59%",
    "dir": 1,
    "prev_price": "77.49",
    "mcapval": "348.20 Cr",
    "mcap": "Micro Cap",
    "scripcode": 512600,
    "symbol": "",
    "ind_name": "Trading & Distributors",
    "ind_code": 49,
    "sector_id": 79,
    "indexname": "India SENSEX",
    "isin": "INE307N01014",
    "curr_date": "Jun 24, 09:38 AM",
    "curr_time": "09:39 AM",
    "last_traded_at": "Jun 24, 09:38 AM IST",
    "bse_nse_vol": "202 ",
    "exc_status": "Active",
    "traded_date": "Jun 24, 2026",
    "traded_date_str": "2026 06 24",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astal-lab-157295-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Astal Laboratories Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-hold-by-marketsmojo-4062952",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstalLaboratori_mojoScore_4062952.png",
        "date": "2026-06-19 10:11:29",
        "description": "Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Astal Laboratories Declines 2.63%: 4 Key Factors Shaping This Week’s Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-declines-263-4-key-factors-shaping-this-weeks-performance-4053182",
        "imagepath": "",
        "date": "2026-06-14 16:02:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Q4 FY26 results reveal explosive revenue growth but profit concerns</p>\n                    <p><strong>2 June:</strong> Flat quarterly financial trend amid mixed performance reported</p>\n                    <p><strong>3 June:</strong> Quality grade upgraded signalling improving fundamentals</p>\n                    <p><strong>3 June:</strong> Valuation shifts highlight renewed price attractiveness</p>\n                    <p><strong>5 June:</strong> Week closes at Rs.71.91, down 2.63%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.73.85</..."
      },
      {
        "title": "Astal Laboratories Ltd Upgraded to Hold on Mixed Financial and Valuation Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-upgraded-to-hold-on-mixed-financial-and-valuation-signals-4038163",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstalLaboratori_mojoScore_4038163.png",
        "date": "2026-06-08 08:07:21",
        "description": "Astal Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its financial quality, valuation attractiveness, and technical outlook despite a flat recent financial trend. This reassessment comes amid a mixed quarterly performance and evolving market dynamics, positioning the micro-cap stock as a cautious but watchful opportunity for investors."
      },
      {
        "title": "Astal Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4032644",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstalLaboratori_valuationdot_4032644.png",
        "date": "2026-06-03 08:00:10",
        "description": "Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a significant shift in its valuation parameters, moving from a previously very expensive rating to a very attractive valuation grade. This change comes amid a backdrop of mixed returns and sector challenges, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks."
      },
      {
        "title": "Astal Laboratories Ltd Quality Upgrade Signals Improving Business Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-quality-upgrade-signals-improving-business-fundamentals-4032635",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstalLaboratori_qualitydot_4032635.png",
        "date": "2026-06-03 08:00:05",
        "description": "Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a notable upgrade in its quality grading from average to good, reflecting improvements in key business fundamentals. Despite this positive shift, the company’s stock performance remains under pressure, with a 4.58% decline on 3 June 2026 and a year-to-date return lagging behind the Sensex. This article analyses the underlying financial metrics driving the quality upgrade and assesses the implications for investors."
      },
      {
        "title": "Are Astal Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-astal-laboratories-ltd-latest-results-good-or-bad-4032336",
        "imagepath": "",
        "date": "2026-06-02 19:25:17",
        "description": "Astal Laboratories Ltd's latest financial results for the quarter ended March 2026 reflect a complex operational landscape. The company reported net sales of ₹134.05 crores, indicating a significant sequential growth of 156.60% from the previous quarter. However, year-on-year comparisons are less favorable, with net sales growth of 74.35% compared to 91.59% in the same quarter last year. \n\nNet profit for the March 2026 quarter was ₹7.68 crores, which represents a substantial increase of 225.42% from the preceding quarter. Yet, this figure is overshadowed by a year-on-year decline of 60.22%, highlighting challenges in maintaining profitability despite revenue growth. The profit after tax margin also saw a notable contraction, falling to 5.73% from 11.67% in the previous year, indicating that the rapid revenue expansion has come at the expense of profitability.\n\nOperating margins improved slightly to 7.60% fr..."
      },
      {
        "title": "Astal Laboratories Ltd Reports Flat Quarterly Financial Trend Amid Mixed Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-reports-flat-quarterly-financial-trend-amid-mixed-performance-4028921",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstalLaboratori_fintrenddot_4028921.png",
        "date": "2026-06-02 08:00:04",
        "description": "Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite a robust surge in net sales, the company’s profitability metrics have deteriorated sharply, prompting a downgrade in its Mojo Grade from Strong Sell to Sell as of 16 February 2026."
      },
      {
        "title": "Astal Laboratories Q4 FY26: Explosive Revenue Growth Masks Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/astal-laboratories-q4-fy26-explosive-revenue-growth-masks-profitability-concerns-4030831",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstalLaboratori_quaterlyResult_4030831.png",
        "date": "2026-06-01 21:30:35",
        "description": "Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, delivered a stunning 156.60% quarter-on-quarter revenue surge in Q4 FY26, yet the stock tumbled 3.24% to ₹71.46 on June 01, 2026, as investors grappled with sharply compressed margins and deteriorating profitability metrics. With a market capitalisation of ₹328.00 crores, the company's explosive topline expansion has failed to translate into bottom-line strength, raising critical questions about operational efficiency and sustainable growth."
      },
      {
        "title": "Are Astal Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-astal-laboratories-ltd-latest-results-good-or-bad-4023727",
        "imagepath": "",
        "date": "2026-05-30 19:40:00",
        "description": "Astal Laboratories Ltd's latest financial results for Q3 FY26 present a complex picture characterized by significant revenue growth alongside notable challenges in profitability. The company reported a remarkable year-on-year revenue increase of 261.27%, reaching ₹52.24 crores, which reflects strong market traction for its pharmaceutical intermediates and bulk drug offerings. This growth is particularly impressive when compared to the previous year's performance, where revenue growth was substantially lower at 71.94%.\n\nHowever, this explosive revenue growth is juxtaposed with a decline in net profit, which amounted to ₹2.36 crores, representing a year-on-year decrease of 5.22%. The operating margin has also faced considerable pressure, collapsing to 6.80% from 22.96% in the same quarter last year, indicating a significant erosion of profitability. This margin compression raises concerns about the sustainabi..."
      }
    ],
    "total": 156,
    "sid": "157295",
    "stock_news_url": "https://www.marketsmojo.com/news/astal-laboratories-157295"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "22-Jun-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Astal Laboratories Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L74120UP1993PLC015605</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>13.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Mahendra Kumar <br/> Designation: Company Secretary and Compliance officer <br/> EmailId: mahendrakumar@astallabs.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: BALAYOGISWARA RAO PEDDINTI <br/> Designation: Chief Financial Officer <br/> EmailId: balu@astallabs.com</div> </div> <div> <br/> Date: 22/06/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Jun-2026",
      "details": "Newspaper publication.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "02-Jun-2026",
      "details": "Submission of newspaper publication for financial results for the quarter and year ended March 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Astal Laboratories Ltd is Rated Hold by MarketsMOJO

2026-06-19 10:11:29

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Astal Laboratories Declines 2.63%: 4 Key Factors Shaping This Week’s Performance

2026-06-14 16:02:48

Key Events This Week

1 June: Q4 FY26 results reveal explosive revenue growth but profit concerns

2 June: Flat quarterly financial trend amid mixed performance reported

3 June: Quality grade upgraded signalling improving fundamentals

3 June: Valuation shifts highlight renewed price attractiveness

5 June: Week closes at Rs.71.91, down 2.63%

Week Open

Rs.73.85Read full news article

Astal Laboratories Ltd Upgraded to Hold on Mixed Financial and Valuation Signals

2026-06-08 08:07:21

Astal Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its financial quality, valuation attractiveness, and technical outlook despite a flat recent financial trend. This reassessment comes amid a mixed quarterly performance and evolving market dynamics, positioning the micro-cap stock as a cautious but watchful opportunity for investors.

Read full news article

Astal Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-06-03 08:00:10

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a significant shift in its valuation parameters, moving from a previously very expensive rating to a very attractive valuation grade. This change comes amid a backdrop of mixed returns and sector challenges, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.

Read full news article

Astal Laboratories Ltd Quality Upgrade Signals Improving Business Fundamentals

2026-06-03 08:00:05

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a notable upgrade in its quality grading from average to good, reflecting improvements in key business fundamentals. Despite this positive shift, the company’s stock performance remains under pressure, with a 4.58% decline on 3 June 2026 and a year-to-date return lagging behind the Sensex. This article analyses the underlying financial metrics driving the quality upgrade and assesses the implications for investors.

Read full news article

Are Astal Laboratories Ltd latest results good or bad?

2026-06-02 19:25:17

Astal Laboratories Ltd's latest financial results for the quarter ended March 2026 reflect a complex operational landscape. The company reported net sales of ₹134.05 crores, indicating a significant sequential growth of 156.60% from the previous quarter. However, year-on-year comparisons are less favorable, with net sales growth of 74.35% compared to 91.59% in the same quarter last year. Net profit for the March 2026 quarter was ₹7.68 crores, which represents a substantial increase of 225.42% from the preceding quarter. Yet, this figure is overshadowed by a year-on-year decline of 60.22%, highlighting challenges in maintaining profitability despite revenue growth. The profit after tax margin also saw a notable contraction, falling to 5.73% from 11.67% in the previous year, indicating that the rapid revenue expansion has come at the expense of profitability. Operating margins improved slightly to 7.60% fr...

Read full news article

Astal Laboratories Ltd Reports Flat Quarterly Financial Trend Amid Mixed Performance

2026-06-02 08:00:04

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite a robust surge in net sales, the company’s profitability metrics have deteriorated sharply, prompting a downgrade in its Mojo Grade from Strong Sell to Sell as of 16 February 2026.

Read full news article

Astal Laboratories Q4 FY26: Explosive Revenue Growth Masks Profitability Concerns

2026-06-01 21:30:35

Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, delivered a stunning 156.60% quarter-on-quarter revenue surge in Q4 FY26, yet the stock tumbled 3.24% to ₹71.46 on June 01, 2026, as investors grappled with sharply compressed margins and deteriorating profitability metrics. With a market capitalisation of ₹328.00 crores, the company's explosive topline expansion has failed to translate into bottom-line strength, raising critical questions about operational efficiency and sustainable growth.

Read full news article

Are Astal Laboratories Ltd latest results good or bad?

2026-05-30 19:40:00

Astal Laboratories Ltd's latest financial results for Q3 FY26 present a complex picture characterized by significant revenue growth alongside notable challenges in profitability. The company reported a remarkable year-on-year revenue increase of 261.27%, reaching ₹52.24 crores, which reflects strong market traction for its pharmaceutical intermediates and bulk drug offerings. This growth is particularly impressive when compared to the previous year's performance, where revenue growth was substantially lower at 71.94%. However, this explosive revenue growth is juxtaposed with a decline in net profit, which amounted to ₹2.36 crores, representing a year-on-year decrease of 5.22%. The operating margin has also faced considerable pressure, collapsing to 6.80% from 22.96% in the same quarter last year, indicating a significant erosion of profitability. This margin compression raises concerns about the sustainabi...

Read full news article

View All News